Palvella Therapeutics PVLA Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's stock-based comp?
- Palvella Therapeutics (PVLA) reported stock-based comp of $3.38M in Q1 2026.
- How has Palvella Therapeutics's stock-based comp changed year-over-year?
- Palvella Therapeutics's stock-based comp increased by 208.6% year-over-year, from $1.09M to $3.38M.
- What is the long-term trend for Palvella Therapeutics's stock-based comp?
- Over 3 years (2021 to 2025), Palvella Therapeutics's stock-based comp has grown at a 7.1% compound annual growth rate (CAGR), from $5.22M to $6.4M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.